Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 50mg | $84.97 | $1.70/mg | In stock | Jul 8 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| 11-3-46136 | Apr 2026 | 99.7% | MDx BioAnalytical Laboratory | Endotoxin | Unverified | View |
| 11-3-46057 | Feb 2026 | 99.8% | BioRegen | — |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. GHK-Cu is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does BioLongevity Labs sell GHK-Cu?
Yes — BioLongevity Labs currently lists GHK-Cu in 1 variant starting at $84.97 ($1.70/mg).
Is BioLongevity Labs's GHK-Cu third-party tested?
Yes — Disclosed Labs has indexed 13 Certificates of Analysis for BioLongevity Labs's GHK-Cu, with the most recent showing 99.7% purity. BioLongevity Labs holds an overall trust grade of C (78/100) across all 327 COAs on file.
What is BioLongevity Labs's trust grade for GHK-Cu?
BioLongevity Labs has an overall Disclosed Labs trust grade of C (78/100), computed from 327 COAs across all peptides. The most recent GHK-Cu COA was issued by MDx BioAnalytical Laboratory.
Where is the cheapest GHK-Cu?
As of the latest data, Sunrise Bioresearch offers GHK-Cu at $0.09/mg — compare with BioLongevity Labs's listing at $1.70/mg. See the full GHK-Cu price comparison.
Is GHK-Cu legal to buy?
GHK-Cu is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| Confirmed |
| View |
| 11-3-45600 | Nov 2025 | 99.8% | BioRegen | — | Confirmed | View |
| 11-3-45929 | Nov 2025 | 99.8% | BioRegen | Endotoxin | Confirmed | View |
| — | Oct 2025 | 99.7% | MDx BioAnalytical Laboratory | — | Confirmed | View |
| 11-3-45937 | Oct 2025 | 99.9% | BioRegen | — | Confirmed | View |
| — | Oct 2025 | 99.8% | MDx BioAnalytical Laboratory | — | Confirmed | View |
| 11-2-45785 | Sep 2025 | 99.8% | BioRegen | — | Confirmed | View |
| QC251139 | Aug 2025 | 98.8% | MDx BioAnalytical Laboratory | — | Confirmed | View |
| 12-2-45804 | Aug 2025 | — | BioRegen | Endotoxin | Confirmed | View |
| BIOLABS2010 | Apr 2025 | 99.2% | BioRegen | — | Confirmed1 flag | View |
| — | — | 99.8% | SafeCert Labs | — | Unverified | View |
| L1164 | — | — | Unknown | Heavy metals | Unverified | View |